Adlai Nortye Ltd
Research Adlai Nortye Ltd (ANL) on Bullrun: market cap USD 884.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 884.83M
- Financial periodQ4 2025
- RevenueUSD 5.00M
- Net income-USD 35.53M
- Free cash flow-USD 33.64M
Valuation Snapshot
latest market cap is USD 884.83M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 884.83M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 56.80M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 98.89M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 331.73M | n/a | n/a | n/a |
About Adlai Nortye Ltd
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adlai Nortye Ltd's market cap?
Adlai Nortye Ltd's market capitalization is USD 884.83M.
What does Adlai Nortye Ltd do?
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors.